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Abstract Cytochrome P450 2D6 (CYP2D6) is one of
the most important cytochromes P450 in humans.
Resonance Raman data from the T309V mutant of
CYP2D6 show that the substitution of the conserved
I-helix threonine situated in the enzyme’s active site
perturbs the heme spin equilibrium in favor of the
six-coordinated low-spin species. A mechanistic hypo-
thesis is introduced to explain the experimental
observations, and its compatibility with the available
structural and spectroscopic data is tested using quan-
tum-mechanical density functional theory calculations
on active-site models for both the CYP2D6 wild type
and the T309V mutant.
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Abbreviations
5c Five-coordinated
6c Six-coordinated
cDNA Complementary DNA
CYP Cytochrome P450
DFT Density functional theory
DX Dextromethorphan hydrobromide
DZP Double zeta valence plus polarization
HS High spin
LS Low spin
RR Resonance Raman
STO Slater-type orbital
TZP Triple zeta valence plus polarization
Introduction
Cytochromes P450 (CYPs) are enzymes responsible for
the oxidative biotransformation of a large variety of
endogenous and exogenous substrates, like steroids,
carcinogens and drugs, and have been found in virtu-
ally all organisms [1]. In human drug metabolism, one
of the most important CYP isoforms is CYP2D6. This
hepatic enzyme is involved in the phase I oxidative
metabolism of about 30% of currently marketed drugs,
including much prescribed antidepressants, b-blockers,
opioids and antiarythmics [2]. The enzyme is known for
its genetic polymorphisms and gene multiplicities, even
increasing its clinical relevance [3]. Structural studies
on CYP2D6 are of crucial importance to understand
how this enzyme works and to be able to predict the
metabolism of new (druglike) compounds [4].
A common structural feature in all CYPs, including
CYP2D6 [5], is the distal helix (I-helix) positioned
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above the heme plane, which constitutes an important
part of the enzyme’s active site (Fig. 1a). Previously,
we demonstrated the critical role of the I-helix residue
T309 in the mechanism of oxidation by CYP2D6 [6].
Similar results were found after mutation of the
homologous threonine residues T302 and T303 in
rabbit CYP2B4 and CYP2E1, respectively [7, 8]. The
I-helix threonine is highly conserved in CYPs and
seems to be a key residue in the monooxygenation
reaction. It has been studied in many CYPs with
mutagenesis, spectroscopic and crystallographic tech-
niques [9]: depending on the specific isoenzyme, the
distal threonine has been attributed a variety of roles
besides oxygen activation and proton delivery [9, 10],
including electron transfer [11], substrate recognition
[12] and control of heme spin state equilibrium [12–17].
This multiplicity of roles, as indicated by the diversity
of results obtained from different CYPs, has been
interpreted as a lack of a universal role of this residue,
which might have instead distinct functions within the
CYP superfamily [9, 14, 17].
In this study, spectroscopy is used to probe the
active site of the wild type and the T309V mutant of
CYP2D6 to establish whether the mutation influences
the heme characteristics. Resonance Raman (RR), a
vibrational spectroscopy technique based on inelastic
scattering of laser radiation in resonance with an elec-
tronic transition of a chromophore, is used to obtain
information about several properties of the heme
prosthetic group [18, 19]. The heme-iron oxidation
state, spin state and coordination state, as well as
conformational changes of the vinyl and propionate
side chains of the porphyrin macrocycle can be inferred
from RR spectra [19]. Furthermore, the Fe–CO
stretching frequency of the ferrous CO–heme complex
is sensitive to variations in the electrostatic potential of
the heme distal pocket induced by substrate-binding or
mutated residues [20, 21]. RR was successfully em-
ployed in the past to study many CYPs [19] and the
effects of mutations in their active site [22–27],
including those of the conserved I-helix threonine
[11, 28, 29].
Besides spectroscopic data, a computational ap-
proach is employed to rationalize the experimental re-
sults. Although experimental data on threonine mutants
are already available for many CYPs, theoretical
descriptions have been only carried out at a classical
force-field level for the T302A mutant of CYP2B4 [30]
and at a density functional theory (DFT) level for the
T252A mutant of CYP101 [31]. Quantum-mechanical
DFT calculations can reliably predict the relative
energies of the various electronic states of iron(II) and
iron(III) porphyrins and have been previously used to
study the resting state as well as further steps of the
catalytic cycle of CYPs [31–35]. Therefore, this method,
in absence of decisive experimental proof in favor of a
specific model, is used in the present work to test the
compatibility of a definite hypothesis with available
structural and spectroscopic data on the CYP2D6 active
site. In particular, through a computational analysis of
Fig. 1 a The cytochrome P450 2D6 (CYP2D6) active site as
obtained from crystallographic data (PDB 2F9Q). The heme
(coordinated by C443) and part of the I-helix are shown in color
with the heme and the residues A305 and T309 as ball-and-stick
models. Hydrogen atoms are not modeled in the PDB file. b
Optimized geometry of the CYP2D6 active site model, i.e., the
A305–G306–M307–V308–T309 part of the I-helix and the iron
porphyrin part of the heme catalytic center of CYP2D6 in its
doublet (low-spin) electronic spin state, with a water molecule
coordinated to the iron (position 1). c Geometry of the CYP2D6
active-site model corresponding to a second energy minimum
(water in position 2). Carbon, nitrogen, oxygen and hydrogen
atoms are colored green, blue, red and white, respectively. Iron
and sulfur atoms are colored orange. Distances are in angstroms
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the wild-type and the T309V-mutant active-site struc-
tures, interactions are investigated between residue
T309, the heme moiety and a water molecule located
above the heme in the resting state.
Materials and methods
Materials
The pSP19T7LT plasmid containing in tandem the
complementary DNAs (cDNAs) of human CYP2D6
with a C-terminal His6-tag and the human NADPH-
CYP reductase, was used as described before [6].
Escherichia coli JM109 was obtained from DSMZ
(Braunschweig, Germany). Dextromethorphan hyd-
robromide (DX) was obtained from Sigma (St. Louis,
MO, USA). All other chemicals were of analytical
grade and were obtained from standard suppliers.
Expression and purification of the enzymes
The pSP19T7LT plasmids containing the wild type or
the T309V mutant of CYP2D6 cDNA were trans-
formed into E. coli strain JM109. Expression and
membrane isolation was carried out as described in [6].
Membranes were resuspended in 0.5% of the original
culture volume of potassium phosphate–glycerol buffer
(50 mM potassium phosphate buffer, pH 7.4, 10%
glycerol) and the enzymes were purified, using nickel
affinity chromatography as described in [6]. CYP con-
centrations were determined by CO difference
absorption spectra according to the procedure of
Omura and Sato [36], with a Pharmacia Ultrospec 2000
spectrometer.
RR spectroscopy
Spectroscopic measurements were conducted using a
homebuilt Raman microscope in a backscattering
configuration. A Zeiss microscope (D-7082 with ·40
objective, numerical aperture 0.60, working distance
2 mm) was coupled to a single monochromator
(Instruments, Metuchen, NJ, USA) with a mounted
grating with 2,400 grooves per millimeter and a CCD
camera (DV-420OE, Andor Technologies, Belfast,
UK). The 413.1-nm line of a continuous-wave Kr ion
laser (Coherent Innova 300c, Coherent, Santa Clara,
CA, USA) and the 457.9-nm line of a continuous-
wave Ar ion laser (Spectra Physics 2000–336, Newport
Corp., Mountain View, CA, USA) were used for
excitation, and the Rayleigh scattered light was
removed using third Millennium edge long pass filters
(Omega Optical, Bratleboro, VT, USA). Laser pow-
ers of 5 mW (at 413.1 nm) and 1 mW (at 457.9 nm)
at the sample were used throughout the experiments.
The sloping background of the spectra was subtracted
using a baseline fitted to the experimental data with
the Andor CCD camera software. The fitting of
experimental data with Lorentzian functions was
performed with PeakFit 4.12 (SeaSolve Software,
Richmond, CA, USA). For RR measurements, a
1-mm-diameter glass capillary was filled with 10 ll of
various concentrations (1–50 lM) of CYP2D6 in
potassium phosphate–glycerol buffer and put in a
spinning capillary holder under the microscope
objective. To measure substrate binding, substrate
concentrations of 5–10 mM were used, leading to a
500–1,000-fold excess of substrate with respect to the
enzyme (saturating conditions, as indicated by the Ks
reported for the substrates [6]). No further spectral
changes were detected upon increasing substrate
concentration, indicating that all the CYP2D6 in the
sample was bound to the substrate [37]. To obtain
the ferrous CO complexes, oxygen was removed from
the CYP2D6 samples (with or without substrate) by
stirring under a nitrogen atmosphere; then the sam-
ples were reduced by adding 5 ll of 25 g l–1 sodium
dithionite (in potassium phosphate–glycerol buffer)
to 20 ll of enzyme in the same buffer, and were
exposed to CO for 2–3 min while stirring. During all
measurements, the capillary containing the sample
was kept spinning to minimize local heating and
photodissociation of the iron-bound CO. Before and
after every RR measurement, CYP integrity was
monitored by CO difference absorption spectroscopy.
Computational details
Model
The crystal structure at 3.0-A˚ resolution of the sub-
strate-free human CYP2D6 (PDB 2F9Q) [5] was used
as the starting structure for the DFT calculations. The
computational model includes only a small part of the
distal I-helix from A305 to T309, the heme moiety and
the proximal C443. In this model, the isopropyl amino
acid side chain of V308 is replaced by a methyl sub-
stituent and the 2-(methylthio)ethyl side chain of M307
is replaced by a hydrogen. These alterations are ap-
plied to considerably reduce the computational cost
and are usually justified by the fact that these amino
acid side chains are not pointing toward the heme
cavity [38]. Likewise, the heme substituents are
replaced by hydrogens, and the C443 proximal
heme ligand is mimicked by a thiolate anion (HS–).
J Biol Inorg Chem (2007) 12:645–654 647
123
Moreover, a water molecule is added above the heme
iron to generate a six-coordinated (6c) resting state, as
suggested by spectroscopic data (see ‘‘Results’’ and
‘‘Discussion’’). This results in an 89-atom model for the
active site of the wild-type protein. The T309V mutant
is approximated by replacing the alcohol moiety of the
T309 by a methyl substituent to give V309 instead.
These two models are used to provide a rationale for
the differences between the observed relative amounts
of high spin (HS) and low spin (LS) in the wild-type
and T309V-mutant enzymes of CYP2D6.
Method
DFT calculations were performed with the Amsterdam
Density Functional program [39–41]. The atomic
orbitals on the atoms of the alcohol moiety of T309,
the carbonyl group of A305, the thiolate anion, iron
and nitrogens of the heme moiety were described by
an uncontracted triple zeta valence plus polarization
(TZP) Slater-type orbital (STO) basis set. A double
zeta valence plus polarization (DZP) STO basis set
was used for the other atoms of the I-helix and the
atoms of the periphery of the heme. The inner cores
of carbon, nitrogen, and oxygen (1s2) and those of
sulfur and iron (1s22s22p6) were kept frozen. The
exchange–correlation potential was based on the
newly developed generalized gradient approximation
exchange functional OPTX in combination with the
nonempirical PBE correlation functional (OPBE)
[42, 43]. The OPBE density functional was chosen
because of its demonstrated superior performance in
describing the spin states and electronic structures for
iron complexes, which is of crucial importance in the
present study [32]. The model was based on
the geometry of 2F9Q [5] and is fully optimized for
the doublet spin state (LS). This structure was used as
a starting structure for the linear transit calculations
(geometry scan) in which the water molecule
was moved toward the threonine by decreasing the
Owater–OThr distance to yield the five-coordinated (5c)
heme moiety. In these geometry optimizations, the
positions of the a carbons of A305 and T309 and two
porphyrin meso carbons were fixed to mimic the
rigidity of the protein tertiary structure (see supple-
mentary material). Subsequently, analogous geometry
optimizations of the LS geometries obtained were
performed for the sextet spin states (HS).
The energy profiles for the mutant enzyme model
were obtained by the same procedure for each
structure of the wild-type profile in which the thre-
onine hydroxyl moiety was replaced by a methyl
substituent.
Results
Enzymes expression and purification,
UV–vis absorption spectroscopy
Recombinant expression followed by affinity chroma-
tography purification yielded approximately 60 nmol
CYP2D6 per liter of cultured E. coli, in the case of the
wild type and the T309V mutant of CYP2D6. The
enzymes were pure, as judged by the observation of a
single band of 55 kD on a Coomassie brilliant blue
stained sodium dodecyl sulfate–polyacrylamide gel.
The absolute absorbance spectra of oxidized and
reduced CO-bound, wild-type and T309V-mutant
CYP2D6 are shown in Fig. 2. Both enzymes show
characteristic strong absorption bands at 418 and
448 nm, in their resting state and reduced CO-bound
form, respectively. No significant differences are ob-
served in the position or the relative intensity of
absorption bands between the spectra of the wild type
and the T309V mutant of CYP2D6, even by use of
spectral subtraction (data not shown). An amount of
P420 (inactive CYP, observed as a band at 420 nm in
the reduced CO-bound form) was present in the both
the wild-type and T309V-mutant samples, to approxi-
mately the same extent.
Fig. 2 Electronic absorption spectra of 1 lM purified wild-type
and T309V-mutant CYP2D6, in the oxidized resting state form
(solid line) and the reduced CO-bound form (dashed line)
648 J Biol Inorg Chem (2007) 12:645–654
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RR spectroscopy
The RR spectra of the wild type and the T309V mutant
of CYP2D6 in the resting state (i.e., without substrate)
are at first sight rather similar (Fig. 3). In both cases,
the most intense band at 1,372 cm–1 is attributed to the
m4 vibrational mode, indicative for an oxidized heme
iron atom [19].
The high-frequency region of the RR spectrum of
the wild-type enzyme (Fig. 4) is indicative for a pre-
dominantly 6cLS oxidized heme, in agreement with a
previous study [27]. The bands at 1,501, 1,582 and
1,635 cm–1 are attributed to the m3, m2 and m10 vibra-
tional modes for a 6cLS heme, respectively [19].
However, the slight asymmetry of m3 suggests the
presence of another band at lower wavenumbers,
characteristic of a 5cHS species. A better fit of the
spectroscopic data for wild-type CYP2D6 is obtained
when including bands at 1,486, 1,567 and 1,623 cm–1
for, respectively, the m3, m2 and m10 vibrational modes of
a 5cHS heme species in addition to the 6cLS bands.
The presence of 5cHS heme species in the RR
spectrum of the wild type is more evident when com-
pared with the spectrum of the T309V mutant (Fig. 4).
Although the two spectra seem similar, the difference
spectrum of the two enzymes shows an intensity in-
crease for the bands characteristic of a 6cLS species
and a concomitant decrease of the m3, m2 and m10
vibrational modes that are typical for a 5cHS heme.
Therefore, in the T309V mutant the content of 5cHS is
decreased compared with that in the wild type, with a
concomitant increase of the 6cLS fraction. In the presence of saturating amounts of the sub-
strate DX, the bands distinctive of the 5cHS species (m3
and m2 at 1,486 and 1,567 cm
–1, respectively) increase in
intensity, whereas the intensity of the corresponding
bands for the 6cLS species (m3 and m2 at 1,501 and
1,582 cm–1, respectively) diminishes for both the wild
type and the T309V mutant of CYP2D6 (Fig. 5). The
intensity ratio between the 6cLS and 5cHS m3 bands (at
1,501 and 1,486 cm–1, respectively) is higher in the
T309V mutant than in the wild type for substrate-
bound CYP2D6.
The T309V mutation does not alter the Fe–CO
stretching frequency (mFe–CO) observed at 476 cm
–1 in
both the reduced CO-bound wild-type and the T309V-
mutant CYP2D6 (Fig. 6). As previously observed [27],
in the RR spectrum of wild-type CYP2D6 mFe–CO in-
creases by 5 cm–1 upon addition of saturating amounts
of DX. In the same experimental conditions, the mFe–CO
band of the T309V mutant broadens toward higher
wavenumbers, indicating that a shift, although less
evident, is taking place similarly to that in the wild
type.
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Fig. 3 Resonance Raman spectra of wild-type (WT) and mutant
(T309V) CYP2D6. Spectra were acquired as described in
‘‘Methods.’’ Excitation wavelength 413.1 nm, laser power at
the sample 5 mW, accumulation time 600 s
Fig. 4 Spin marker band region of the resonance Raman spectra
of wild-type (WT) and mutant (T309V) CYP2D6, together with
their difference spectrum. Excitation wavelength 413.1 nm, laser
power at the sample 5 mW, accumulation time 600 s. The
Lorentzian functions used to fit the spectrum of the wild-type
enzyme (see ‘‘Methods’’) are represented as solid lines (for high-
spin marker bands) or dotted lines (low-spin marker bands).
Frequencies of high-spin marker bands are reported in bold
J Biol Inorg Chem (2007) 12:645–654 649
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DFT calculations
The optimized geometry of the enzyme’s resting state
was modeled by adding a water molecule above the
heme using the crystal structure of the human CYP2D6
(Fig. 1b). The root mean square deviation of the
optimized backbone of the I-helix and the corre-
sponding residues in the experimental structure is only
0.28 A˚, confirming that the modifications applied to
the side chains of residues M307 and V308 in the model
do influence the conformation of the I-helix in the
active site. The water molecule is bound to the iron
(water position 1 in Fig. 1b, Fe–O distance is approx-
imately 2.2 A˚), yielding a 6cLS iron porphyrin complex
that is energetically favored over the 6cHS state by
7.5 kcal mol–1. The water molecule is hydrogen-bon-
ded to the carbonyl oxygen atom of the A305-G306
peptide bond (approximately 1.9 A˚). The hydroxyl
moiety of the threonine amino acid residue (T309) also
forms a weak hydrogen bond to this amide oxygen
(approximately 2.6 A˚). When the water molecule
migrates from the iron to the threonine moiety, a
hydrogen bond is formed (Fig. 1c) in which the thre-
onine alcohol group acts as a hydrogen-bond donor;
the conformation with the OH group acting as a
hydrogen-bond acceptor is 6.6 kcal mol–1 less stable.
The energy profiles upon migration of the water
molecule toward the threonine (i.e., from position 1 to
2) for both the LS and the HS states are shown as solid
curves in Fig. 7. This movement of the water molecule
results in the increase of the relative energy of the LS
state and a new local minimum (5cLS) is obtained,
which is 1.4 kcal mol–1 higher in energy with respect to
the energy of the starting structure (6cLS). The relative
energy of the HS state increases slightly upon short-
ening the threonine–water distance and decreases
again to reach a new minimum that is lower in energy.
There is a spin crossover at a Owater–OThr distance of
approximately 3.1 A˚ and a global minimum for the HS
state is obtained. In the corresponding structure, the
water molecule is hydrogen-bonded to the T309 and
occupies a second position in the active-site pocket,
further referred to in the following sections as position
2 (Fig. 1c).
Fig. 5 Spin marker bands region of the resonance Raman
spectra of wild-type (WT) and mutant (T309V) CYP2D6 in the
presence (solid lines) and in the absence (dotted lines) of the
substrate dextromethorphan hydrobromide. The spectral differ-
ence between the enzyme in the presence and in the absence of
substrate is shown for the spin marker band m3. Excitation
wavelength 413.1 nm, laser power at the sample 5 mW, accu-
mulation time 600 s
Fig. 6 Low-frequency resonance Raman spectra of the reduced
CO-bound CYP2D6 wild type (WT) and mutant (T309V), in
presence and in absence of dextromethorphan hydrobromide
(DX). Excitation 457.9 nm, laser power at the sample 1 mW,
accumulation time 600 s
650 J Biol Inorg Chem (2007) 12:645–654
123
Replacement of the threonine with valine in each of
the structures followed by partial geometry optimiza-
tions results in different energy profiles for the mutant
(dashed curves in Fig. 7). For both the HS and the LS
mutant models, after a small initial decrease of
approximately 2 kcal mol–1 which yields minima at an
Owater–OThr distance of 3.9 and 3.5 A˚ for the LS and
HS states, respectively, the relative energy increases
steeply as the water approaches position 2, for which,
in contrast to the wild type, no minima are found.
The interaction between residue T309 and the CO
adduct was studied by full geometry optimization of
the CO-bound iron porphyrin model species for both
the wild type and the T309V mutant, showing that the
bond distances, bond dissociation energies and bond
orders of the Fe–C ” O moiety are virtually identical
(Table 1). Population analysis of the CO adduct shows
a substantial iron backdonation into the empty p*
orbitals of CO, with occupation numbers of approxi-
mately 0.2 electrons for both the wild type and the
mutant.
The superimposed geometries of the fully optimized
and experimental structures, of the partially optimized
structures of the T309V mutant with water in positions
1 and 2, and of the fully optimized structures of
the CO-bound species for both the wild type and
the T309V mutant are available as supplementary
material.
Discussion
In the resting state, the CYP heme iron atom is gen-
erally observed as oxidized (Fe3+), and mainly in the
6cLS state with a water molecule (or hydroxyl ion) as
the sixth distal ligand trans to the endogenous cystei-
nate ligand [44]. Although no distal water ligand is
reported in the structure determined by X-ray dif-
fraction [5] (Fig. 1a), both electronic absorption and
RR spectroscopy indicate that wild-type CYP2D6 is
predominantly 6cLS. The present DFT calculations
show that the resting state is clearly a 6cLS state, in
agreement with spectroscopic data (Fig. 1b). In addi-
tion to experimental data, DFT calculations suggest a
network of hydrogen bonds between the residue A305,
the distal water ligand and the residue T309, in which
T309 and the water ligand are too far to interact di-
rectly. The same structural pattern, where the distal
water is hydrogen-bonded to an alanine (four positions
before the conserved threonine in the primary se-
quence), which is in turn weakly hydrogen bonded to
the threonine, is also present in the experimental
structures of other bacterial and mammalian CYPs
[45–47].
Moreover, in agreement with the DFT calculations
for CYP2D6, in all these structures the conserved
threonine is too far to hydrogen-bond the distal water
ligand. The absence of a direct interaction between the
heme axial ligand and the threonine in CYP2D6 is
experimentally corroborated by the absence of differ-
ences in the electronic absorption and RR spectra of
the CO adducts of the wild type and T309V, where a
CO ligand occupies the position of the water molecule
in the resting state. In fact, hydrogen bonding or direct
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Fig. 7 The relative doublet (low spin, filled circles) and sextet
(high spin, filled squares) energies for the active-site model of the
wild-type CYP2D6 with respect to the distance between the
oxygen atoms of the water molecule and the threonine alcohol
side group. The dashed line represents the low-spin (open circles)
and high-spin (open squares) energy profiles for the mutant
model, obtained by replacing threonine with valine. LS low spin,
HS high spin, 5c five-coordinated, 6c six-coordinated
Table 1 Selected bond distances, bond dissociation energies
[DE(Fe–CO)], bond orders and p*(CO) orbital population of the
CO–heme model for the wild type and the T309V mutant of
cytochrome P450 2D6
Fe–CO Fe–C ” O
Wild type Mutant Wild type Mutant
Distance (A˚) 1.824 1.851 1.147 1.146
DE(Fe–CO)
(kcal mol–1)
–24.6 –24.2 – –
Mayer bond order 0.21 0.20 0.52 0.52
p*(CO) population – – 0.19 e– 0.18 e–
J Biol Inorg Chem (2007) 12:645–654 651
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electrostatic interaction between T309 and the axial
CO would alter the extent of backdonation of iron dp
electrons to the empty CO p* orbitals, shifting signifi-
cantly both the Fe–CO stretching frequency in RR
spectra and the absorption maximum in the UV–vis
absorption spectra of the reduced CO-bound heme [48,
49]. A similar situation is observed for the T268A
mutant of CYP102 A1, whose CO adduct has a UV–vis
absorption spectrum identical to that of the wild type
[9, 14]. The absence of a significant interaction between
the CO adduct and residue T309 is supported by DFT
calculations on CO-bound CYP2D6, showing that the
Fe–CO bond energy, bond order, and the extent of
Fe ﬁ CO backdonation are virtually the same for
both the wild type and the mutant (Table 1).
Besides the predominant 6cLS state, the 5cHS spe-
cies is present as a minor component in RR spectra of
CYP2D6 (Fig. 4). The occurrence of the 5cHS species
could not be detected in UV–vis absorption spectra,
probably because of its small amount. RR spectra have
more, narrower bands which are usually better re-
solved than UV–vis spectra at room temperature,
making it easier to detect asymmetries or weak
shoulders when using spectral subtraction or fitting.
The presence of the 5cHS species in the resting state is
not unusual and it has been reported in RR spectra of
other bacterial and mammalian CYPs [50–53]. A shift
of the spin equilibrium toward the 5cHS state, in which
the heme is no longer ligated to an axial water mole-
cule, is often observed when a substrate (like DX for
CYP2D6; Fig. 5) is present in the heme pocket, per-
turbing the iron-bound water molecule directly, or
through inducing conformational changes in the en-
zyme [44]. However, this substrate-induced spin shift
often does not lead to a pure 5cHS species, but rather
to a mixture of the two species, with 6cLS still signifi-
cantly present, like in the case of CYP2D6 with DX.
The decrease of 5cHS and the concomitant increase
of the 6cLS content in the RR spectra of the T309V
mutant of CYP2D6 indicate that the residue T309 is
structurally involved in the spin equilibrium. This role is
preserved in the presence of DX as the substrate itself
perturbs the wild-type and mutant spin equilibria to the
same extent, which is evident from the spectral sub-
traction of the m3 region of the resting state from the
substrate-bound state (Fig. 5). The same conclusion can
be drawn from RR spectra of the CO adduct of the two
enzymes in the presence of substrate. Moreover, the
similar affinity of the two enzymes for DX (as was judged
from optical titration experiments [6] as well as model-
ing studies [54]) does not indicate T309 to be involved in
substrate binding in CYP2D6. This strongly suggests
that the difference in the 6cLS-to-5cHS ratio in the RR
spectra between the substrate-bound wild-type and
mutant enzyme is not due to different binding modes of
DX, but rather to a difference caused by the T309V
mutation, as observed in the absence of a substrate.
An altered spin equilibrium upon mutation of the
conserved threonine residue has been reported for
many other CYPs [12, 14–17, 55, 56]. Notably in the
T268A mutant of CYP102 A1, which share with the
optimized CYP2D6 computational model the hydro-
gen-bonding pattern ‘‘distal water–alanine–threonine,’’
the alteration is in favor of the 6cLS, like in CYP2D6
[12, 14].
In an effort to rationalize the experimental obser-
vations, we looked for an explanatory model, com-
patible with our spectroscopic data, which could be
tested using available quantum-mechanical methods.
The absence of direct interactions between T309 and
the axial ligand indicates that T309 exerts its influence
on the spin equilibria of CYP2D6 indirectly.
It might be argued that the increase of the 6cLS
species in the T309V mutant is due to an increased
solvent accessibility of the binding pocket caused by a
mutation-induced conformational change. However,
this hypothesis is incompatible with the spectroscopic
data on the CO adduct, which rule out any significant
change in polarity in the heme pocket due to the
T309V mutation. A more plausible explanation is that
T309 in CYP2D6 stabilizes, by means of hydrogen
bonding, an alternative position of the water that is
distant enough from the iron center to yield a 5cHS
state. This model has also been proposed to account for
spin equilibria in substrate-bound CYP102 A1 and its
T268A mutant [13, 14]. Substitution of the threonine
with a valine should eliminate the hydrogen-bonding
interaction and perturb the equilibrium by destabiliz-
ing the 5cHS state in favor of the 6cLS species, as
observed from spectroscopic data.
DFT calculations clearly support this hypothesis,
showing the destabilization of the 5cHS state upon the
T309V mutation. In agreement with the experimental
observation of a small amount of 5cHS in the resting
state of the wild type, a spin transition from LS to HS
occurs upon moving the water molecule from position 1
to 2, and a second energy minimum has been found for
the water molecule hydrogen-bonded to T309 (Figs. 1c,
7). Replacing the threonine with a valine results in a
relative destabilization of the structure in which water is
in position 2, most likely because of the absence of
hydrophilic interactions between the water and the va-
line. This relative destabilization of the 5c heme with the
water in position 2 will result in the occurrence of a
higher relative amount of the 6cLS heme species in the
T309V mutant of CYP2D6 with respect to the wild type.
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Although the computational model of the CYP2D6
active site used in the present study only includes a few
amino acids and the iron–porphyrin complex, and
therefore does not take into account the rest of the
protein, it provides a clear rationale for the observed
experimental data. Unfortunately, an evident limit of
this model is the inability to include the substrate and
to study its influence on the spin equilibrium of the
substrate-bound enzymes, for which extended models
and methods have to be used. However, it should be
stressed that experimental data indicate that the role of
T309 in the CYP2D6 spin equilibrium is independent
of that of DX; therefore, it is reasonable to assume that
the implications of our model for the role of T309
would still be valid for the substrate-bound enzymes.
Conclusions
On the basis of RR data, it is concluded that the T309V
mutant of CYP2D6 has an altered spin equilibrium
with respect to the wild-type enzyme, with a relative
higher amount of 6cLS species at the expense of the
5cHS species, in both the resting state and the sub-
strate-bound forms. Apparently, there is no direct
interaction between residue T309 and the heme sixth
ligand, suggesting an indirect mechanism of action on
the spin equilibrium. Spectroscopic data also indicate
that the T309V mutation does not significantly alter the
polarity of the heme environment, excluding an in-
creased number of water molecules in the heme pocket
as the reason for the altered spin state. DFT calcula-
tions show that a simple model, involving a water
molecule alternatively occupying two positions inside
the heme pocket corresponding to two different spin
states, is able to explain the experimental data. In this
model, the position corresponding to the 5cHS state is
stabilized by a hydrogen bond with T309, and a T309V
mutation will induce an increase of the 6cLS species, as
experimentally observed.
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